Roche’s fenebrutinib this week scored a mid-stage win in relapsing multiple sclerosis, while Sanofi’s tolebrutinib met the primary endpoint in a Phase III trial for progressive MS but flopped in two ...

Chris Gibson, PhD, Recursion’s co-founder and CEO, discusses exclusively with GEN Edge his company’s ambitious plans to ...

Although the latest news from the laboratory was mixed for pharmaceutical company Sanofi (NASDAQ: SNY) on Tuesday, investors gave the company the benefit of the doubt. They bid the share price up ...

After a tough year, Exscientia folds into Recursion to create an AI superpower Recursion saw no improvements on patient-reported outcomes (PROs), or physician-led measures, after 12 months of ...

Exscientia also has a really substantial collaboration [oncology and immunology/inflammation, up to $5.2 billion, launched in 2022] with Sanofi. What’s most exciting is, those are all future ...

Good morning! Today, we discuss the woman who spearheaded progress in multiple myeloma for decades, see mixed but promising results from Sanofi’s multiple sclerosis drug, and hear why All of Us ...

Recursion Pharmaceuticals on Tuesday said results from a mid-stage trial showed its lead experimental drug to be safe, the first readout in a series of important data disclosures for the AI drug ...

The po­ten­tial of Sanofi’s close­ly-watched BTK in­hibitor in mul­ti­ple scle­ro­sis is com­ing in­to clear­er view amid plans to nar­row the fo­cus of the French com­pa­ny’ … ...

But, in the GEMINI trials, tolebrutinib failed the primary endpoint of besting Sanofi’s own approved MS drug Aubagio when it came to reducing relapses over up to 36 months. Trying to find the ...

By Ludwig Burger (Reuters) -Sanofi's most advanced multiple sclerosis drug candidate has missed the main goal of two late-stage trials to treat relapsing forms of the disease, but in a positive ...

Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially clearing the way for regulatory approval, although in two other studies ...